SQI Diagnostics To Partner With Innovative Cardiac Event Prediction Test

SQI Diagnostics (TSXV:SQD, OTCQX:SQIDF) has entered a partnership with a company in California to evolve their cardiac event prediction test.
As quoted in the press release:

In the agreement, SQI will transform this customer’s multi-biomarker test into an SQI-based multiplex test, with kits to be manufactured at SQI’s state-of-the-art facility in Toronto.  The agreement also calls for the automation of the test on SQI’s sqid lite system which would then be sold to the customer to run the tests at its CLIA laboratory.  In addition to running the test in their own laboratory, SQI’s customer also plans to sell both the test kit and SQI automation systems to its ever-expanding global customer base.  These customers are renowned cardiologists, hospitals, and reference laboratories around the world.
This customer’s test marks a major advancement in medicine’s ability to predict the chances of a heart attack before it happens.  It is the first test of its kind to detect heart attack risk factors in patients through the use of a blood test. The test’s performance attributes were presented at the 12th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease to a distinguished faculty of global scientists, researchers, and practicing clinicians.  As reported, the test can predict the likelihood that patients will experience a heart attack (ACS event) within a 5-year period – allowing physicians to implement potentially life-saving prevention plans.
“We’re excited to be the technology platform upon which this exciting new test will be based and to add another great customer to our diagnostics segment portfolio,” said Andrew Morris, CEO of SQI Diagnostics. “We believe the test will transform the way cardiovascular testing and cardiac event prediction is performed. Clearly, the commercial potential for this predictive test is very promising as is illustrated by the esteemed and growing list of customer clinics using this important predictive diagnostic tool.  We believe this product will add significantly to our 2017 revenues and expect further growth beyond 2017”
About SQI Diagnostics
SQI Diagnostics is the life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com.

Click here to read the full press release.